We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
- Authors
Mittica, Gloria; Genta, Sofia; Aglietta, Massimo; Valabrega, Giorgio
- Abstract
Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. The standard treatment for advanced stage is the combination of optimal debulking surgery and platinum-based chemotherapy. Nevertheless, recurrence is frequent (around 70%) and prognosis is globally poor. New therapeutic agents are needed to improve survival. Since EOC is strongly immunogenic, immune checkpoint inhibitors are under evaluation for their capacity to contrast the "turn off" signals expressed by the tumor to escape the immune system and usually responsible for self-tolerance maintenance. This article reviews the literature on anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies in EOC and highlights their possible lines of development. Further studies are needed to better define the prognostic role of the immune checkpoint inhibitors, to identify predictors of response and the optimal clinical setting in EOC.
- Subjects
OVARIAN epithelial cancer; CANCER chemotherapy; GENE expression; CELL-mediated cytotoxicity; T cells; CANCER treatment
- Publication
International Journal of Molecular Sciences, 2016, Vol 17, Issue 7, p1169
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms17071169